التفاصيل البيبلوغرافية
| العنوان: |
77-LB: Improved A1C and TIR in Adults with T2D Participating in a CGM-Driven Virtual Diabetes Clinic. |
| المؤلفون: |
MAJITHIA, AMIT R., KUSIAK, COCO, LEE, AMY ARMENTO, COLANGELO, FRANCIS R., ROMANELLI, ROBERT, ROBERTSON, SCOTT, MILLER, DAVID P., ERANI, DAVID M., DIXON, RONALD F., ZISSER, HOWARD |
| المصدر: |
Diabetes; 2020 Supplement, Vol. 69, pN.PAG-N.PAG, 1p |
| مستخلص: |
The Onduo Virtual Diabetes Clinic (VDC) for people with T2D combines a mobile app, remote personalized lifestyle coaching, connected devices and live video consultations with board-certified endocrinologists for medication management and prescription of real-time CGM devices for intermittent use. This prospective single-arm study enrolled adults with a baseline A1c of ≥8.0% to ≤12.0% from 2 primary care centers to participate in the VDC program. The primary outcome was change in A1c from baseline at 4 mo. Secondary outcomes included change in CGM-based (Dexcom G6) glycemic parameters. Participants (n=55) were: 57.3±11.6 yr, 40.0% female and BMI 33.7±7.2. A1c decreased significantly by -1.6%±1.0 (p<0.001) from 8.9%±1.0 to 7.3%±0.9 at 4 mo. Stratified by baseline A1c 8.0% to 9.0% (n=36) and >9.0% (n=19), A1c decreased by -1.2%±0.6 and -2.4%±1.3 (both p<0.001). CGM metrics (n=43) are presented in the Table. Percent time in range (TIR) increased significantly from below target to target levels at follow-up. The results indicate that participation in the VDC for 4 mo was associated with significant improvement in A1c, increased TIR, decreased time in hyperglycemia and no increase in hypoglycemia. In conclusion, the VDC has potential to support people with T2D and their clinicians between office visits by increasing access to specialty care and advanced diabetes technology including CGM. Disclosure: A.R. Majithia: Consultant; Self; Onduo. C. Kusiak: Employee; Self; Verily Life Sciences LLC. Stock/Shareholder; Self; Verily Life Sciences LLC. A. Armento Lee: None. F.R. Colangelo: None. R. Romanelli: Advisory Panel; Self; Novo Nordisk Inc. S. Robertson: Other Relationship; Self; Verily Life Sciences LLC. D.P. Miller: Employee; Self; Verily Life Sciences LLC. Stock/Shareholder; Self; Verily Life Sciences LLC. D.M. Erani: None. R.F. Dixon: Employee; Self; Onduo. H. Zisser: Employee; Self; Verily Life Sciences LLC. Stock/Shareholder; Self; Verily Life Sciences LLC. [ABSTRACT FROM AUTHOR] |
|
Copyright of Diabetes is the property of American Diabetes Association and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
